pp-057 Injection

For retinal diseases including proliferative vitreoretinopathy (PVR), glaucoma, and diabetic retinopathy; conditions associated with inflammation, fibrosis, and pathological extracellular matrix remodeling. Clinical stage: Preclinical development. Anti-autotaxin RNA aptamer (chemically modified oligonucleotide therapeutic). Mechanism / Target: Selective inhibitor of autotaxin (ATX), an enzyme responsible for generating lysophosphatidic acid (LPA). Excessive ATX–LPA signaling contributes to fibrosis, inflammation, scarring, and pathological wound-healing responses in retinal disease. RBM-006 blocks ATX activity to reduce fibrotic proliferation and inflammation. Route / form: Intended for intravitreal administration (based on preclinical ophthalmic use). Differentiation: Targets ATX/LPA pathway — a mechanism not addressed by anti-VEGF agents. Offers potential benefit in diseases where fibrosis and scarring drive progression, such as PVR and diabetic retinopathy, and may complement or work independently of VEGF-targeted therapies.